In this article included in The Globalisation of the Pharmaceutical Industry, the authors draw on their experience to develop lessons on how to establish a sustainable life sciences eco-system in middle-income countries (MICs) and low-income countries (LICs). They highlight the importance of different types of government policy (industrial policy, the regulatory framework, intellectual property, and improving access to medicines) and how success requires different stakeholders (public and private, international and national) to work together.
To read the article, click here.
CRA Insights: A landscape assessment of newborn screening (NBS) in Europe
Newborn screening (NBS) has become an integral part of many public health programs.1 NBS programs have minimized patient suffering which results from extended...